10x Genomics Inc Dossier
Qualitative Analysis
Business overview
10x Genomics, Inc. (NASDAQ: TXG) is a leading life sciences technology company that designs, develops, and sells instruments, consumables, and software for analyzing biological systems at high resolution. The company's proprietary platforms—Chromium for high-throughput single-cell analysis, Visium for spatial transcriptomics, and Xenium for in situ profiling—enable researchers to map biological complexity at cellular and subcellular levels. Operating on a classic "razor-and-blade" business model, 10x Genomics derives a substantial portion of its recurring revenue from high-margin consumables used repeatedly by its global installed base of over 6,500 instruments.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Launching and scaling Atera, a new in situ spatial biology platform engineered to deliver high-throughput, whole-transcriptome spatial analysis with single-cell sensitivity at scale (up to 800 samples per year).
Expected impact: Aims to unlock larger biopharma and translational research contracts where high throughput and data standardization are critical, driving long-term consumables growth.
A new service program enabling researchers to directly submit samples for whole-transcriptome spatial analysis on the Atera platform without needing to purchase the instrument upfront.
Expected impact: Broadens accessibility to high-throughput spatial biology for smaller labs and projects, reducing procurement friction and expanding the customer pipeline.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To expand 10x Genomics' capabilities in proteomics and support its broader vision for richer multiomic approaches (combining transcriptomic and proteomic measurements) across single-cell and spatial platforms.
Financial impact: The terms of the transaction were not disclosed; 10x Genomics stated the transaction will not meaningfully impact its near-term financial outlook.
To acquire combinatorial indexing and quantum barcoding technologies, enhancing the throughput, affordability, and scalability of single-cell sequencing on the Chromium platform.
Financial impact: Acquired for $30 million in upfront cash and stock, plus additional contingent milestone payments.
Strategic Partnerships
Collaborating alongside Broad Clinical Labs to launch the Spatial Tissue Embedding Learning Atlas (STELA). STELA will utilize 10x's Xenium platform (and eventually Atera) to profile up to 100,000 patient tissue specimens, creating the world's largest clinically linked spatial biology dataset to power Bioptimus' biological foundation model, M-Optimus.
Terms: Terms of the collaboration were not disclosed.
Establishing the ImmuneScape initiative to study transplant organ rejection at cellular resolution. The project leverages 10x's Xenium spatial and Chromium Flex single-cell platforms to map immune mechanisms underlying antibody-mediated rejection and microvascular inflammation.
Terms: Terms of the collaboration were not disclosed.